# US 12,178,916 B2 · Compositions and treatment procedures for the treatment of pathogenic infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,916 B2
- Document ID: US12178916B2
- Status: Granted
- Kind: B2
- Application number: 16/610,662
- Filed: 2018-05-04
- Published: 2021-08-26
- Granted: 2024-12-31
- Earliest claimed: 2017-05-04
- Applicants: Walter Schaub
- Inventors: Walter Schaub
- Web page: https://patentgrep.com/patent/US12178916B2

## CPC

- A61K 9/2009: {Inorganic compounds}
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61P 33/06: Antimalarials
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions, and dosage forms thereof, comprising an oxidation agent selected from sodium, potassium, magnesium or calcium hypochlorite, chlorite or chlorate, an artemisinin composition or a derivative or combination thereof as a primary active oxidizing agent, which primary active oxidizing agent is provided in a form to enable release or generation of a hypochlorite ion or hypochlorous acid, a chlorite ion or chlorous acid, a chlorate ion or chloric acid, neutral or ionic chlorine dioxide or other derivative thereof from the respective hypochlorite, chlorite, or chlorate. The pharmaceutical compositions may be employed or administered to a warm-blooded mammalian subject to be treated for combatting pathogenic infections or invasions.

## Claims

### Claim 1

A pharmaceutical composition comprising:
an essentially solid solvent-free composition, said essentially solid solvent-free composition comprising:
one or more oxidising components selected from the group consisting of: sodium hypochlorite and potassium hypochlorite,
wherein said one or more oxidising components are dispersible or soluble in an aqueous liquid medium,
wherein dispersal or dissolution of said one or more oxidising components in an aqueous medium comprising at least one dispersible or soluble solid solvent-free acid component, being provided in conjunction or in combination with said one or more oxidising components comprised in the solid solvent-free composition, results in the release or generation of a molecular or ionic chlorine dioxide or a derivative thereof as an active agent within the respective aqueous liquid medium,
wherein said essentially solid solvent-free composition comprises an absorbable therapeutically effective non-toxic amount of said one or more oxidising components absorbable by transit through the buccal cavity of a warm-blooded mammalian subject,
wherein said one or more oxidising components are intimately admixed with at least one dispersible or soluble solid solvent-free acid component selected from the group consisting of: anhydrous citric acid,
wherein an amount of an alkali metal carbonate or bicarbonate salt is provided in conjunction with the solid solvent-free composition, and
wherein said pharmaceutical composition is provided as oral dosage form in a soluble sublingual dosage form, adapted to be retained in the mouth or buccal cavity by the warm-blooded mammalian subject and thereby allowing for a sublingual release of said one or more oxidising component within an acidic aqueous medium provided by simultaneous sublingual release of said at least one dispersible or soluble solid solvent-free acid component into salivary contents of the buccal cavity and thereby enabling direct systemic absorption of the active agent by absorption sites offered by the sublingual surfaces of the lining of the buccal cavity of the warm-blooded mammalian subject,
wherein the composition comprises a proportion of sodium bicarbonate or potassium bicarbonate or a combination thereof, which is in excess of about 30% w/w of the total weight of the composition, and
wherein a proportion of the one or more oxidising component in the pharmaceutical composition is selected to provide a concentration of the one or more oxidising component within the aqueous medium available in a selected body cavity of the mammalian subject that is greater than about 10 ppm and less than about 100 ppm.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1,
wherein the composition comprises an amount of the one or more oxidising component not exceeding about 5% w/w of the total weight of the composition, and
wherein an amount of a dispersible or soluble alkali or alkaline earth metal chloride to provide and act as an inert composition diluent and stabiliser component of the composition and aqueous liquid medium within which the composition is dispersed or dissolved.

### Claim 3 (depends on 1)

A sublingual lozenge comprising the pharmaceutical composition according to claim 1.